Patents Assigned to ZymoGenetics, Inc.
  • Use of truncated cysteine IL28 and IL29 Mutants to treat cancers and autoimmune disorders
    Patent number: 8313739
    Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: November 20, 2012
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • METHODS OF TREATING INFLAMMATION USING SOLUBLE IL-17RA/RC FUSION PROTEINS
    Publication number: 20120289684
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Application
    Filed: June 4, 2012
    Publication date: November 15, 2012
    Applicant: ZYMOGENETICS, INC.
    Inventors: Steven D. Levin, Mark W. Rixon, Zeren Gao
  • Antibodies to cytokine receptor ZCYTOR17
    Patent number: 8309692
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: November 13, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
  • IL-21 ANTAGONISTS
    Publication number: 20120282250
    Abstract: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 8, 2012
    Applicant: ZYMOGENETICS, INC.
    Inventors: Pallavur V. SIVAKUMAR, Stephen R. JASPERS
  • Methods of using IL-31 to treat chronic obstructive pulmonary disease (COPD)
    Patent number: 8298524
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: October 30, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • Method of treating fibrproliferative disorders
    Patent number: 8298534
    Abstract: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: October 30, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Methods of treating IL-TIF associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors
    Patent number: 8287866
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: October 16, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Stavros Topouzis
  • Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
    Patent number: 8283448
    Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: October 9, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Kevin M. Klucher, Wayne R. Kindsvogel, Pallavur V. Sivakumar, Katherine E Henderson
  • Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist
    Patent number: 8268773
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: September 18, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Steven D. Levin, Rolf E. Kuestner, Zeren Gao, Stephen R. Jaspers, Janine Bilsborough
  • ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES
    Publication number: 20120225065
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 6, 2012
    Applicant: ZYMOGENETICS, INC.
    Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
  • ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20120207761
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Application
    Filed: March 22, 2012
    Publication date: August 16, 2012
    Applicant: ZYMOGENETICS, INC.
    Inventors: Wenfeng XU, Wayne KINDSVOGEL, Yasmin A. CHANDRASEKHER, Stacey R. DILLON, Joyce M. LEHNER, Anthony W. SIADAK, Pallavur V. SIVAKUMAR, Margaret Dow MOORE
  • Anti-human IL-21 monoclonal antibodies
    Patent number: 8241629
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: August 14, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
  • Methods of treating inflammation using soluble IL-17RA/RC fusion proteins
    Patent number: 8242072
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: August 14, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Mark W. Rixon, Zeren Gao
  • Cytokine protein family
    Patent number: 8231866
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: July 31, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
  • Anti-human IL-21 monoclonal antibodies
    Patent number: 8226948
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
  • Cytokine zalpha11 ligand antibodies
    Patent number: 8227575
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • IL-23 antagonists
    Patent number: 8227579
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: July 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, James W. West, Robert Mabry, Brent Meengs, Steven D. Levin
  • IL-21 antagonists
    Patent number: 8222374
    Abstract: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: July 17, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
  • ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES
    Publication number: 20120177655
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 12, 2012
    Applicant: ZYMOGENETICS, INC.
    Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
  • Methods of treating inflammatory disease using a soluble IL-20 receptor
    Patent number: 8217008
    Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: July 10, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox